Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

We talk about them below, but examples include: Off-label marketing risk Safety Affordability We’ll also show how to screen through the GLP-1 drug companies. When combining insights from ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, potentially limiting patients’ ability to access it.

Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...

The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...

Federal regulators have warned a Waco company that its human amniotic products are “unlicensed” and “unapproved,” and that ...